All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Adrian Minson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with chimeric antigen receptor (CAR) T-cell therapies in mantle cell lymphoma (MCL)?
TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?
Minson explains why there is a drive to develop new therapies that will lead to more durable remissions in patients with MCL, and how immunotherapeutic agents, such as CAR T-cell therapies, have been beneficial but not without their challenges. Minson then reviews the positive impact of combining ibrutinib with CAR T-cell therapy and examines data on response, survival, and toxicity from the TARMAC trial (NCT04234061), in which this combination was used as a treatment option for MCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
What’s new in mantle cell lymphoma?
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität München, Munich, DE. We asked, What’s new in mantle cell...
Review | Therapies available or in clinical development for patients with aggressive mantle cell lymphoma in 2020
Chemoimmunotherapy with rituximab followed by autologous stem cell transplant (auto-HSCT) has been the gold standard and the only...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox